XOMA (XOMA) Competitors

Innoviva (NASDAQ:INVA) and XOMA (NASDAQ:XOMA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.

Which has better valuation and earnings, INVA or XOMA?

Innoviva has higher revenue and earnings than XOMA. XOMA is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$352.75M	3.22	$179.72M	$0.69	26.33
XOMA	$4.76M	59.90	-$40.83M	-$3.48	-6.96

Does the media prefer INVA or XOMA?

In the previous week, Innoviva had 3 more articles in the media than XOMA. MarketBeat recorded 4 mentions for Innoviva and 1 mentions for XOMA. XOMA's average media sentiment score of 1.63 beat Innoviva's score of 1.05 indicating that XOMA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XOMA	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts prefer INVA or XOMA?

XOMA has a consensus price target of $72.00, suggesting a potential upside of 197.46%. Given XOMA's higher probable upside, analysts clearly believe XOMA is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
XOMA	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is INVA or XOMA more profitable?

Innoviva has a net margin of 18.31% compared to XOMA's net margin of -151.34%. Innoviva's return on equity of 20.84% beat XOMA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	18.31%	20.84%	11.38%
XOMA	-151.34%	-24.95%	-9.64%

Does the MarketBeat Community favor INVA or XOMA?

XOMA received 138 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 65.82% of users gave XOMA an outperform vote while only 57.55% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Innoviva	Outperform Votes 301 57.55%	Underperform Votes 222 42.45%
XOMA	Outperform Votes 439 65.82%	Underperform Votes 228 34.18%

Which has more risk & volatility, INVA or XOMA?

Innoviva has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, XOMA has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Do institutionals and insiders believe in INVA or XOMA?

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 95.9% of XOMA shares are owned by institutional investors. 1.7% of Innoviva shares are owned by company insiders. Comparatively, 7.2% of XOMA shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Innoviva beats XOMA on 9 of the 17 factors compared between the two stocks.